SCIENTIFIC PANEL ON Nutrition, Novel Foods and Food Allergens 151st Plenary meeting



2-3 July 2024 14:30-18:00 / 09:00-12:30 AGENDA

Location: EFSA, Parma

D1: 2 July

10.	Ttem
1	Welcome and apologies for absence
2	Adoption of the agenda
3	Declarations of interest
4	Round table presentation of NDA Panel Members and EFSA NIF Unit/Teams
5	Election of Panel Chair and Vice Chairs
6	NDA Panel & EFSA Teams: roles & working practice
7	The work programme of NDA Panel
8	NDA Panel Working Groups
D2: 3 July	
No.	Item
9	Other scientific topics for information
9.1	Draft opinion on the nutritional safety and suitability of a specific protein
	hydrolysate manufactured by Fonterra Co-operative Group Ltd derived from a whey protein concentrate and used in an infant formula and follow-on formula (EFSA-Q-2021-00339)
9.2	a whey protein concentrate and used in an infant formula and follow-on
9.2 9.3	a whey protein concentrate and used in an infant formula and follow-on formula (EFSA-Q-2021-00339)
	a whey protein concentrate and used in an infant formula and follow-on formula (EFSA-Q-2021-00339) Cumulative exposure on HiMOs
9.3	a whey protein concentrate and used in an infant formula and follow-on formula (EFSA-Q-2021-00339) Cumulative exposure on HiMOs Biomarker of effects
9.3 9.4	a whey protein concentrate and used in an infant formula and follow-on formula (EFSA-Q-2021-00339) Cumulative exposure on HiMOs Biomarker of effects Risk-Benefit assessment